RecruitingPhase 4NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Sponsor
Janssen Research & Development, LLC
Enrollment
295 participants
Start Date
Mar 9, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study
Interventions
DRUGCilta-cel
Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Locations(50)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05201781
Related Trials
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT0725851133 locations
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
NCT068761421 location
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT0617988873 locations
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT0709545225 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535166 locations